A comparison of pulmonary exacerbations with single and multiple organisms in patients with cystic fibrosis and chronic Burkholderia cepacia infection

J Infect. 2003 Jan;46(1):56-9. doi: 10.1053/jinf.2001.1077.

Abstract

Study objectives: To compare pulmonary exacerbations with single and multiple organisms in patients with chronic Burkholderia cepacia infection.

Design: Data was collected over a 23-month period and for each of the patients two episodes of pulmonary exacerbation were identified, one with B. cepacia isolated as the sole respiratory pathogen and the other with one or more coinfecting organisms grown from the sputum culture.

Setting: Regional tertiary referral center for Respiratory Medicine and Adult Cystic Fibrosis Center for Northern Ireland, Belfast City Hospital.

Patients: Adult (over 16 years) CF patients with chronic (more than 4 years) B. cepacia complex infection who attended the Belfast City Hospital between January 1997 and November 1998.

Measurements: Forced expiratory volume in 1s, forced vital capacity, forced expiratory flow rate 25-75, C-reactive protein, leucocyte count and body mass index were measured before and after two weeks of treatment and analysed for any differences in change between the two episodes.

Results: All variables in both groups improved following treatment except for body mass index, which remained unchanged. No significant differences between the measurements were identified on comparison of single (monomicrobial) and multiple (polymicrobial) isolate episodes.

Conclusion: Patients with chronic B. cepacia infection who develop a pulmonary exacerbation improve, as reflected by clinical and biochemical markers, following IV antibiotic treatment. Pulmonary exacerbations with multiple organisms are no more severe than those where only B. cepacia is isolated.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Body Mass Index
  • Burkholderia Infections / complications*
  • Burkholderia Infections / drug therapy*
  • Burkholderia Infections / microbiology
  • Burkholderia cepacia / isolation & purification
  • Chronic Disease
  • Cystic Fibrosis / complications*
  • Female
  • Humans
  • Leukocyte Count
  • Male
  • Pseudomonas aeruginosa / isolation & purification
  • Respiratory Tract Infections / complications
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / microbiology*
  • Stenotrophomonas maltophilia / isolation & purification

Substances

  • Anti-Bacterial Agents